CRMD Stock Analysis: CorMedix | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 641m USD | 12M Return: -39.5% | US21900C3088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.95M
Qual. Beats: 0
Rev. Trend: 95.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CorMedix Inc. is a U.S.-based biopharmaceutical company that develops and commercializes therapeutic products for life-threatening diseases and conditions, with a particular focus on reducing infection risk in vulnerable patient populations. Its lead product candidate, DefenCath, is an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections (CRBSIs) in adult kidney failure patients undergoing hemodialysis.
The company operates within the small-cap pharmaceuticals segment of the health care sector, a category that typically includes late-stage clinical and early-commercialization biopharmaceutical firms. CorMedix was incorporated in 2006 (originally as Picton Holding Company), adopted its current name in January 2007, and is headquartered in Parsippany, New Jersey, within the broader Northeastern U.S. pharmaceutical industry corridor. Its business model centers on bringing a single, specialized hospital-administered product through regulatory approval and into a niche market of dialysis-dependent patients, a population with elevated exposure to catheter-associated infections.
- DefenCath commercial sales ramp after FDA approval
- CMS reimbursement status determines hospital adoption pace
- Cash burn raises dilution risk through future equity offerings
| Net Income: 187.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.28 > 0.02 and ΔFCF/TA 15.80 > 1.0 |
| NWC/Revenue: 63.42% < 20% (prev 178.1%; Δ -114.7% < -1%) |
| CFO/TA 0.28 > 3% & CFO 253.9m > Net Income 187.2m |
| Net Debt (-107.3m) to EBITDA (249.6m): -0.43 < 3 |
| Current Ratio: 2.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (92.5m) vs 12m ago 28.59% < -2% |
| Gross Margin: 82.78% > 18% (prev 95.62%; Δ -12.84% > 0.5%) |
| Asset Turnover: 79.93% > 50% (prev 48.09%; Δ 31.83% > 0%) |
| Interest Coverage Ratio: 77.11 > 6 (EBIT TTM 214.5m / Interest Expense TTM 2.78m) |
| A: 0.32 (Total Current Assets 480.6m - Total Current Liabilities 187.4m) / Total Assets 904.1m |
| B: -0.12 (Retained Earnings -112.0m / Total Assets 904.1m) |
| C: 0.37 (EBIT TTM 214.5m / Avg Total Assets 578.3m) |
| D: 1.04 (Book Value of Equity 460.8m / Total Liabilities 443.2m) |
| Altman-Z'' = 5.31 = AAA |
| DSRI: 0.99 (Receivables 161.3m/42.9m, Revenue 462.2m/121.5m) |
| GMI: 1.16 (GM 95.62% / 82.78%) |
| AQI: 46.69 (AQ_t 0.46 / AQ_t-1 0.01) |
| SGI: 3.81 (Revenue 462.2m / 121.5m) |
| TATA: -0.07 (NI 187.2m - CFO 253.9m) / TA 904.1m) |
| Beneish M = 26.20 (Cap -4..+1) = D |
As of August 22, 2026, the stock is trading at USD 8.20 with a total of 1,473,258 shares traded. Over the past week, the price has changed by +8.75%, over one month by +0.12%, over three months by +1.74% and over the past year by -39.53%.
Current recommended Stop Loss: 7.10 (which is 13.4% or 2.4 ATR below the current price).
CorMedix has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CRMD.
- StrongBuy: 3
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.4 | 87.8% |
P/E Trailing = 3.9005
P/E Forward = 15.7729
P/S = 1.3877
P/B = 1.4402
Revenue TTM = 462.2m USD
EBIT TTM = 214.5m USD
EBITDA TTM = 249.6m USD
Long Term Debt = 144.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.45m USD (from shortTermDebt, last fiscal year)
Debt = 149.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.29m
Net Debt = -107.3m USD (calculated: Debt 149.4m - CCE 256.7m)
Enterprise Value = 534.2m USD (641.5m + Debt 149.4m - CCE 256.7m)
Interest Coverage Ratio = 77.11 (Ebit TTM 214.5m / Interest Expense TTM 2.78m)
EV/FCF = 2.12x (Enterprise Value 534.2m / FCF TTM 251.7m)
FCF Yield = 47.12% (FCF TTM 251.7m / Enterprise Value 534.2m)
FCF Margin = 54.45% (FCF TTM 251.7m / Revenue TTM 462.2m)
Net Margin = 40.49% (Net Income TTM 187.2m / Revenue TTM 462.2m)
Gross Margin = 82.78% ((Revenue TTM 462.2m - Cost of Revenue TTM 79.6m) / Revenue TTM)
Gross Margin QoQ = 75.66% (prev 82.50%)
Tobins Q-Ratio = 0.59 (Enterprise Value 534.2m / Total Assets 904.1m)
Interest Expense / Debt = 1.86% (Interest Expense 2.78m / Debt 149.4m)
Taxrate = 7.98% (16.2m / 203.4m)
NOPAT = 197.4m (EBIT 214.5m * (1 - 7.98%))
Current Ratio = 2.56 (Total Current Assets 480.6m / Total Current Liabilities 187.4m)
Debt / Equity = 0.32 (Debt 149.4m / totalStockholderEquity, last quarter 460.8m)
Debt / EBITDA = -0.43 (Net Debt -107.3m / EBITDA 249.6m)
Debt / FCF = -0.43 (Net Debt -107.3m / FCF TTM 251.7m)
Total Stockholder Equity = 419.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 32.36% (Net Income 187.2m / Total Assets 904.1m)
RoE = 44.64% (Net Income TTM 187.2m / Total Stockholder Equity 419.3m)
RoCE = 38.04% (EBIT 214.5m / Capital Employed (Equity 419.3m + L.T.Debt 144.6m))
RoIC = 28.40% (NOPAT 197.4m / Invested Capital 695.0m)
WACC = 7.36% (E(641.5m)/V(790.9m) * Re(8.68%) + D(149.4m)/V(790.9m) * Rd(1.86%) * (1-Tc(0.08)))
Discount Rate = 8.68% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.55 | Cagr: 23.51%
[DCF] Terminal Value 77.97% ; FCFF base≈163.2m ; Y1≈187.1m ; Y5≈275.3m
[DCF] Fair Price = 54.53 (EV 4.14b - Net Debt -107.3m = Equity 4.25b / Shares 77.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.08 | # QB: 0
Revenue Correlation: 95.36 | Revenue CAGR: 3.35k% | SUE: 0.67 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.10 | Chg30d=-10.64% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=0.49 | Chg30d=-3.17% | Revisions=+25% | GrowthEPS=-76.1% | GrowthRev=+8.1%
EPS next Year (2027-12-31): EPS=0.06 | Chg30d=-31.82% | Revisions=+25% | GrowthEPS=-87.7% | GrowthRev=-15.0%
[Analyst] Revisions Ratio: +29% (up=3, down=1)